CompletedPhase 2ketamine

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Sponsored by VA Office of Research and Development

NCT ID
NCT04560660
Target Enrollment
75 participants
Start Date
2021-03-09
Est. Completion
2025-10-07

About This Study

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.

Conditions Studied

PTSD

Interventions

  • •Ketamine
  • •Midazolam

Eligibility

Age:18 Years - 75 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* male or female Veterans between the ages of 18 and 75 years
* diagnosis of PTSD
* ability to provide written informed consent

Exclusion Criteria:

* females who are currently pregnant or breastfeeding
* current high risk for suicide
* history of moderate/severe head injury
* history of psychosis
* current episode of mania/hypomania
* severe substance and/or alcohol use disorder in the last 6 months

Study Locations (1)

Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Ketamine-enhanced Prolonged Exposure Therapy in PTSD | Huxley